3D Tissue Models
Great Debates and Updates in Breast Cancer
Hilton San Francisco Financial District
750 Kearny Street
San Francisco, California
Great Debates and Updates in Breast Cancer

Schedule of Presentations:

Friday, May 7, 2010
09:00:00 Welcome and introduction William J. Gradishar, Hope S. Rugo
09:10:00 Pre-session audience survey
09:20:00 Debate: Should all patients undergo MRI screening prior to surgery? Are all MRI scans the same? Lawrence J. Solin
09:50:00 Debate: Should trastuzumab be recommended for all women with stage I HER2+ breast cancer? William J. Gradishar, Pamela N. Munster
10:20:00 Didactic: Is gene expression profiling useful in treatment planning for node positive breast cancer? Deborah Toppmeyer
10:40:00 Questions and discussion
10:50:00 Coffee break
11:10:00 Debate: Is continuing trastuzumab in combination with chemotherapy the best treatment strategy following disease progression on trastuzumab? Virginia Kaklamani
11:40:00 Didactic: Emerging therapies for targeting HER2-positive breast cancer: current and future directions Hope S. Rugo
12:00:00 Questions and discussion
12:10:00 Lunch break
13:10:00 Debate: Should additional chemotherapy therapy be given for residual disease at the time of surgery following anthracycline and taxane based neoadjuvant chemotherapy? Mohammad Jahanzeb, Pamela N. Munster
13:40:00 Debate: Should we recommend post mastectomy radiation to all patients with node positive breast cancer? Lawrence J. Solin, Barbara L. Fowble
14:10:00 Didactic: BRCA status: impact on therapeutic decision-making Virginia Kaklamani
14:20:00 Questions and discussion
14:40:00 Coffee break
15:00:00 New Presentation New Presentation New Presentation New Presentation Denise A. Yardley, Mohammad Jahanzeb
15:30:00 Didactic: Role of new and emerging chemotherapy agents targeting the microtubule in the treatment of advanced breast cancer. Denise A. Yardley
16:00:00 Questions and discussion
16:10:00 Adjourn
17:00:00 End of day 1
Saturday, May 8, 2010
08:30:00 Introduction William J. Gradishar, Hope S. Rugo
08:35:00 Pre-session audience survey
08:45:00 Didactic: Optimal hormonal therapy and symptom management for ER-positive menopausal early stage breast cancer Deborah Toppmeyer
09:05:00 Debate: Should bevacizumab be continued beyond disease progression? Hope S. Rugo
10:55:00 Debate: Should ovarian suppression be routinely prescribed for premenopausal women with high risk early stage breast cancer? Terry Mamounas
11:25:00 Questions and discussion
11:35:00 Lunch break
12:35:00 Debate: Bisphosphonates should be routinely used to prevent disease recurrence in women with early stage breast cancer Minetta C. Liu
13:05:00 Didactic: Evolving use of circulating tumor cells and tumor markers in the management of metastatic breast cancer. Minetta C. Liu
13:35:00 Didactic: Novel genetic predictors of therapeutic resistance in breast cancer
13:55:00 Questions and discussion
14:05:00 Post-meeting audience survey
14:15:00 Adjourn
15:05:00 End of day 2
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.